# LevitasBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/levitasbio

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.levitasbio.com
- Total disclosed funding: $62M
- Latest round: Series C (Sep 12, 2022)
- Investors on record: 4

## About

Founded in 2017 by Gozde Durmus, Lars Steinmetz, and Utkan Demirci and based in California, US, LevitasBio, Inc. is a provider of single-cell imaging and profiling technology. As of 2022, Martin Pieprzyk is the CEO of the company. In September 2022, LevitasBio, Inc. raised USD 35 million in Series C funding from Novalis LifeSciences, including Pavilion Capital Partners and Decheng Capital.

The company provides products such as LeviCell EOS, a next-generation sample processing platform with throughput and temperature control; LeviPrep, cold tissue dissociation kits; LeviSelect, specific surface marker enrichment assays; and LeviMetrics, integrated analysis software for real-time on-platform analysis.

The firm offers its technology platform, which is based on magnetic levitation, to initially address the critical need for sample enrichment by providing gentle, label-free viable cell separation free from the deleterious effects imparted by conventional sample preparation methods. LevitasBio's applications include viable cell enrichment, single-cell genomics, CRISPR, tissue processing, and tumor processing.

The organization plans to use the September 2022 funding to accelerate its commercial success through the development of next-generation high-throughput instruments for sample processing and analysis.

## Funding rounds

- Series C, Sep 12, 2022, $35M — Decheng Capital, Pavilion Capital Partners, Novalis LifeSciences
- Series B, Dec 31, 2020, $19M — Decheng Capital, Wuhan Thalys Medical Technology Inc.
- Series A, Jul 27, 2017, $8M — Decheng Capital

## Investors

- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series B, Series C
- Wuhan Thalys Medical Technology Inc. — Series B
- Pavilion Capital Partners (https://capitalatlas.ai/funds/pavilion-capital-partners) — Series C
- Novalis LifeSciences (https://capitalatlas.ai/funds/novalis-lifesciences) — Series C